CAR-NK Cells: A 1.2M CAR-T Replacement Cell Therapy
In recent years, innovative immunotherapies have provided new strategies for the treatment of hematological malignancies. Different from traditional chemotherapy, T cells are genetically engineered so that they can specifically produce cytotoxicity against tumor cells. The success stories related to this are astounding. However, there are still many problems—including insufficient efficacy, insufficient autologous sources, large side effects, and high price—thus limiting clinical use.
CAR-NK cells are a promising alternative with unique cytotoxicity and minimal risk of graft-versus-host disease.
Immunotherapy with chimeric antigen receptor-engineered T cells (CAR-T) has revolutionized the treatment paradigm for relapsed / refractory B -cell malignancies . But despite this, the use of autologous T cells still has certain limitations, including heterogeneity in the quality of collected effector T cells , long cell processing time , limited number of available CAR cells , and high cost.
Considering the antineoplastic effect in haploid hematopoietic stem cell transplantation and adoptive cell therapy for solid tumors and hematological malignancies, NK cells may be a promising alternative. NK cells come from different sources and can be obtained through umbilical cord blood, peripheral blood and induced pluripotent stem cell technology. Their greatest advantage is that they can be applied allogeneically without significant toxic side effects . However, most reports on CAR-NK cells are in the preclinical or early clinical trial stages. In fact, NK cells may be more difficult to engineer, requiring optimization and standardization of expansion and transfection protocols. Additionally, the durability of their efficacy after infusion is a challenge.
With recent advances in the manufacture of CAR-NK cells utilizing their cytolytic capabilities, antibody-dependent cellular cytotoxicity (ADCC) and cytokine induction, "off-the-shelf" allogeneic CAR-NK cells are expected to shine in cancer therapy.
Key Questions Answered
- What are the current limitations of CAR-T cell therapy for cancer treatment?
- Current limitations of CAR-T cell therapy include insufficient efficacy, challenges in obtaining enough autologous sources, potential for significant side effects, and high cost, all of which restrict its broader clinical application. Additionally, there can be heterogeneity in the quality of collected T cells, long processing times, and a limited number of available CAR cells.
- Why are CAR-NK cells considered a promising alternative to CAR-T cell therapy?
- CAR-NK cells are considered a promising alternative because they possess unique cytotoxicity and carry a minimal risk of graft-versus-host disease. They can also be applied allogeneically without significant toxic side effects, and sources like umbilical cord blood, peripheral blood, and induced pluripotent stem cell technology can provide them.
- What challenges exist in the development and use of CAR-NK cell therapy?
- Challenges in CAR-NK cell therapy include that most reports are still in preclinical or early clinical trial stages. It may also be more difficult to engineer NK cells, requiring optimization and standardization of expansion and transfection protocols, and ensuring the durability of their efficacy after infusion is another challenge.
Sources
- No external citations were included in the original source material for this article.
Related Articles
- Research & Industry
Novartis and Bristol Myers Squibb Halt Autoimmune CAR-T Trials: What the Three Deaths Actually Show
Novartis halted eight autoimmune CAR-T trials after three patients died of IEC-HS; Bristol Myers Squibb paused its own as a precaution. What's confirmed, and what's still analyst speculation.
- Research & Industry
FDA Clears First-in-Human Trial of a Dual-Targeted CAR-T Therapy for Colorectal Cancer
The FDA cleared a first-in-human trial of a dual-targeted CAR-T therapy for advanced colorectal cancer and pediatric solid tumors. Why the strategy matters — and what remains unknown.
- Research & Industry
Bispecific Immunotherapy Beats Standard-of-Care in Advanced Biliary Tract Cancer, Phase 3 Trial Shows
A large Phase 3 trial in China found that the dual-acting antibody ivonescimab, paired with chemotherapy, extended survival further than the current international standard of care in advanced biliary tract cancer — though only topline results have been released so far, and the win hasn't yet been replicated outside China.